Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression data from T47D human breast ductal carcinoma cells treated with prolactin and/or NIM811

ABSTRACT: The hormone prolactin is implicated in the pathogenesis of breast cancer, and a subset of prolactin-induced gene expression is mediated by CypA activity. The non-immunosuppressive prolyl isomerase inhibitor, NIM811, is an inhibitor of CypA. We used NIM811 in combination with prolactin treatment in T47D cells to determine differential expression under these conditions.

ORGANISM(S): Homo sapiens

PROVIDER: GSE151635 | GEO | 2020/06/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq data of T47D overexpressing prolactin and the control

Project description:The exact role of prolactin on breast cancer still remains unclear. Clues supportive or unsurpportive for prolactin to be cancer driver are confusing. To clarify the role of autocrine prolactin of breast cancer cells on cancer development, we construct T47D cells overexpressing prolactin.

2023-03-01 | GSE221394 | GEO

RNA-seq data of T47D overexpressing prolactin and the control

Project description:RNA-seq data of T47D overexpressing prolactin and the control

| PRJNA914234 | ENA

Gene expression data from T47D human breast ductal carcinoma cells treated with prolactin and/or NIM811

Project description:Gene expression data from T47D human breast ductal carcinoma cells treated with prolactin and/or NIM811

| PRJNA636697 | ENA

T47D shNT versus T47D shRON

Project description:T47D shNT versus T47D shRON

| PRJNA682172 | ENA

Effects of estradiol, progesterone, prolactin and oxytocin on miRNA levels in T47D human breast cells

Project description:Effects of estradiol, progesterone, prolactin and oxytocin on miRNA levels in T47D human breast cells

| PRJNA1102023 | ENA

Gene expression data from MCF7 breast adenocarcinoma cells treated with prolactin and/or bufexamac

Project description:The hormone prolactin is implicated in the pathogenesis of breast cancer, and a subset of prolactin-induced gene expression is mediated by HDAC6 activity. The NSAID, bufexamac, is a fairly specific inhibitor of HDAC6 and HDAC10. We used bufexamac in combination with prolactin treatment in MCF7 cells to determine differential expression under these conditions.

2016-05-07 | GSE81217 | GEO

Effects of estradiol, progesterone, prolactin and oxytocin on miRNA levels in T47D human breast cells

Project description:The aim of the project was to analyse the levels of miRNA upon hormonal treatment in T47D breast cells

2024-05-08 | GSE264358 | GEO

COX-2 mediates tumor-stromal Prolactin signaling to initiate tumorigenesis [DF]

Project description:Tumor-stromal communication within the microenvironment contributes to initiation of metastasis and may present a therapeutic opportunity. Using serial single cell RNA-sequencing in an orthotopic mouse prostate cancer model, we find upregulation of Prolactin receptor as cancer cells that have disseminated to the lung expand into micrometastases. Secretion of the ligand Prolactin by adjacent lung stromal cells is induced by tumor cell production of the COX-2 synthetic product prostaglandin E-2 (PGE-2). PGE-2 treatment of fibroblasts activates the nuclear orphan receptor NR4A (Nur77), with Prolactin as a major transcriptional target for the NR4A-Retinoid X receptor (RXR) heterodimer. Ectopic expression of Prolactin receptor in mouse cancer cells enhances micrometastasis, while treatment with the COX-2 inhibitor Celecoxib abrogates Prolactin secretion by fibroblasts and reduces tumor initiation. Across multiple human cancers, COX-2, Prolactin, and Prolactin receptor show consistent differential expression in tumor and stromal compartments. Such paracrine crosstalk may thus contribute to the documented efficacy of COX-2 inhibitors in cancer suppression.

2019-02-25 | GSE126158 | GEO

The anti-proliferative effects of progestins in T47D breast cancer cells are tempered by progestin-induction of the ETS transcription factor Elf5.

Project description:Prolactin and progesterone act together to regulate mammary alveolar development, and both hormones have been implicated in breast cancer initiation and progression. Here we show that Elf5, a prolactin-induced ETS transcription factor that specifies the mammary secretory cell lineage, is also induced by progestins in breast cancer cells via a direct mechanism. To define the transcriptional response to progestin elicited via Elf5 we made an inducible Elf5 sh-RNA knock down model in T47D breast cancer cells and used it to prevent the progestin-induction of Elf5. Functional analysis of Affymetrix gene expression data using Gene Ontologies and Gene Set Enrichment Analysis showed enhancement of the progestin effects on cell cycle gene expression. Cell proliferation assays showed a more efficacious progestin-induced growth arrest when Elf5 was kept at baseline levels. These results showed that progestin-induction of Elf5 expression tempered the anti-proliferative effects of progestins in T47D cells, providing a further mechanistic link between prolactin and progestin in the regulation of mammary cell phenotype.

2010-06-17 | GSE22363 | GEO

The anti-proliferative effects of progestins in T47D breast cancer cells are tempered by progestin-induction of the ETS transcription factor Elf5.

2010-07-08 | E-GEOD-22363 | biostudies-arrayexpress